Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wolfram C M Dempke

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Anticancer Research|May 13, 2015
Targeted Therapy for NSCLC--A Double-edged Sword?Wolfram C M Dempke
Translational Lung Cancer Research|March 26, 2015
Gefitinib in non-small-cell lung cancer-an old lesson new re-visitedWolfram C M Dempke
Anticancer Research|December 1, 2010
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitorWolfram C M Dempke, Roland Zippel
Signal Transduction and Targeted Therapy|January 5, 2025
TET2 cascade: a novel regulator of chromatin structure and leukaemogenesisWolfram C M Dempke, Klaus Fenchel
Anticancer Research|May 18, 2012
Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysisFlorian Faussner, Wolfram C M Dempke
Translational Lung Cancer Research|January 5, 2018
Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Wolfram C M Dempke, Klaus Fenchel
Translational Cancer Research|December 19, 2024
Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-reviewWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|July 23, 2021
Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative reviewWolfram C M Dempke, Klaus Fenchel
Anticancer Research|December 1, 2010
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinomaWolfram C M Dempke, Volker Heinemann
Translational Lung Cancer Research|November 10, 2016
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?Wolfram C M Dempke, Klaus Fenchel
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Anticancer Research|May 13, 2015
Targeted Therapy for NSCLC--A Double-edged Sword?Wolfram C M Dempke
Translational Lung Cancer Research|March 26, 2015
Gefitinib in non-small-cell lung cancer-an old lesson new re-visitedWolfram C M Dempke
Anticancer Research|December 1, 2010
Brivanib, a novel dual VEGF-R2/bFGF-R inhibitorWolfram C M Dempke, Roland Zippel
Signal Transduction and Targeted Therapy|January 5, 2025
TET2 cascade: a novel regulator of chromatin structure and leukaemogenesisWolfram C M Dempke, Klaus Fenchel
Anticancer Research|May 18, 2012
Multiple myeloma: myeloablative therapy with autologous stem cell support versus chemotherapy: a meta-analysisFlorian Faussner, Wolfram C M Dempke
Translational Lung Cancer Research|January 5, 2018
Treating epidermal growth factor receptor-mutated non-small cell lung cancer-is dacomitinib the winner?Wolfram C M Dempke, Klaus Fenchel
Translational Cancer Research|December 19, 2024
Targeting C797S mutations and beyond in non-small cell lung cancer-a mini-reviewWolfram C M Dempke, Klaus Fenchel
Translational Lung Cancer Research|July 23, 2021
Has programmed cell death ligand-1 <i>MET</i> an accomplice in non-small cell lung cancer?-a narrative reviewWolfram C M Dempke, Klaus Fenchel
Anticancer Research|December 1, 2010
Ras mutational status is a biomarker for resistance to EGFR inhibitors in colorectal carcinomaWolfram C M Dempke, Volker Heinemann
Translational Lung Cancer Research|November 10, 2016
Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?Wolfram C M Dempke, Klaus Fenchel
Pageof 4